NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements

Report Details Promise of Adaptive Cancer Immunotherapy in Treating Highly Malignant Brain Tumors

Recent Achievements for Glioblastoma/Brain Tumor Treatment to be Addressed in Upcoming Presentation at World Orphan Drug Congress

CLEVELAND, OH / ACCESSWIRE / May 11, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that Dr. Christopher Wheeler, Ph.D., President, StemVax Therapeutics Inc., a division of NovAccess Global and the lead scientist for the Company, has been published along with other research professionals in Oncogene, one of the world's leading cancer journals. The published report details the promise of adaptive cancer immunotherapy, which includes the use of NovAccess' TLR-AD1 drug candidate, in treating highly malignant and aggressive brain tumors.

The report addresses the use of adaptive cancer immunotherapy in treating highly malignant tumors such as glioblastoma multiforme (GBM) and the exploitation of immune enhancement by Isocitrate Dehydrogenase-1 (IDH1), a protein previously known to impact cell metabolism. IDH1 is commonly mutated in brain and other tumors, but the report shows that it surprisingly enhances antitumor responses through a unique molecular mechanism. Because of this, IDH1 increases glioma vaccine efficacy in mice and discerns long-term from short-term survivors after vaccine therapy in GBM patients. Exploiting these findings is anticipated to complement NovAccess' TLR-AD1 vaccine approach, both by selecting the most suitable patients for treatment and maximizing the vaccine's benefits in them.

"We are in awe of the continued and profound work by Dr. Chris Wheeler which we believe brings benefits to both our Company and the healthcare community," said NovAccess Global's Chief Executive Officer Dr. Dwain K. Irvin. "The publication of the work by Chris and other research colleagues is truly impressive since the Oncogene medical journal is a leading publication in which its reviewing editors are among the most respected and accomplished individuals in their fields. We congratulate the authors on the publication and appreciate the awareness being generated for advancements in immunotherapy which is the core mission of NovAccess Global."